📇 Rhumatologue · LE PETIT QUEVILLY CEDEX · (76) · Hospitalier

M NADIR KADRI

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
18 articles scientifiques publiés — formation continue solide
Expérience confirmée
20 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 LE PETIT QUEVILLY CEDEX (76)HospitalierRPPS 10001917748

Expérience confirmée

20ans d'exercice (thèse 2006)

📊 Reconnaissance scientifique : 21/100📝 85 articles publiés🇫🇷 Publications académiques françaises (3)

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Current perspectives on mesenchymal stromal cell therapy for graft versus host disease

Cellular & molecular immunology · 2023

📚 84 citations🎯 RCR 11.27Top 2% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractGraft versus host disease (GvHD) is the clinical condition in which bone marrow-derived mesenchymal stromal cells (MSCs) have been most frequently studied. In this review, we summarize the experience from clinical trials that have paved the way to translation. While MSC-based therapy has shown an exceptional safety profile, identifying potency assays and disease biomarkers that reliably predict the capacity of a specific MSC batch to alleviate GvHD has been difficult. As GvHD diagnosis and staging are based solely on clinical criteria, individual patients recruited in the same clinical trial may have vastly different underlying biology, obscuring trial outcomes and making it difficult to determine the benefit of MSCs in subgroups of patients. An accumulating body of evidence indicates the importance of considering not only the cell product but also patient-specific biomarkers and/or immune characteristics in determining MSC responsiveness. A mode of action where intravascular MSC destruction is followed by monocyte-efferocytosis-mediated skewing of the immune repertoire in a permissive inflammatory environment would both explain why cell engraftment is irrelevant for MSC efficacy and stress the importance of biologic differences between responding and nonresponding patients. We recommend a combined analysis of clinical outcomes and both biomarkers of disease activity and MSC potency assays to identify patients with GvHD who are likely to benefit from MSC therapy.

Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study

Stem cells translational medicine · 2020

📚 59 citations🎯 RCR 3.20Top 15% NIH🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

Abstract Steroid-refractory chronic graft-vs-host disease (cGvHD) contributes to morbidity after allogeneic hematopoietic stem cell transplantation. Here, we report on 11 patients with severe, refractory cGvHD treated with repeated infusions of allogeneic bone marrow-derived mesenchymal stromal cells (MSC) over a 6- to 12-month period. Six patients responded to MSC treatment following National Institutes of Health response criteria, accompanied by improvement in GvHD-related symptoms and quality of life. This response was durable, with systemic immunosuppressive therapy withdrawn from two responders, and a further two free from steroids and tapering calcineurin inhibitors. All responders displayed a distinct immune phenotype characterized by higher levels of naïve T cells and B cells before treatment compared with the nonresponders, and a significantly higher fraction of CD31+ naïve CD4+ T cells. MSC treatment was associated with significant increases in naïve T cells, B cells, and Tregs 7 days after each infusion. Skin biopsies showed resolution of epidermal pathology. CXCL9 and CXCL10 showed differential responses in responder and nonresponder patients. Our data support the use of MSC infusions as treatment for steroid-refractory cGvHD with durable responses. We propose CXCL9 and CXCL10 as early biomarkers for responsiveness to MSC treatment. Our results highlight the importance of the MSC recipient immune phenotype in promoting treatment response. This trial was registered at www.ClinicalTrials.gov as #NCT01522716.

Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis

Immunology and cell biology · 2018

📚 41 citations🎯 RCR 1.57

Lire l'abstract Crossref ↓

AbstractMultiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system involving dysregulated encephalitogenic T cells. Myeloid‐derived suppressor cells (MDSCs) have been recognized for their important function in regulating T‐cell responses. Recent studies have indicated a role for MDSCs in autoimmune diseases, but their significance in MS is not clear. Here, we assessed the frequencies of CD14+HLA‐DRlow monocytic MDSCs (Mo‐MDSCs) and CD33+CD15+CD11b+HLA‐DRlow granulocytic MDSCs (Gr‐MDSCs) and investigated phenotypic and functional differences of Mo‐MDSCs at different clinical stages of MS and in healthy subjects (HC). Increased frequencies of Mo‐MDSCs (P < 0.05) and Gr‐MDSCs (P < 0.05) were observed in relapsing‐remitting MS patients during relapse (RRMS‐relapse) compared to stable RRMS (RRMS‐rem). Secondary progressive MS (SPMS) patients displayed a decreased frequency of Mo‐MDSCs and Gr‐MDSCs compared to HC (P < 0.05). Mo‐MDSCs within RRMS patients expressed significantly higher cell surface protein levels of CD86 and CD163 compared to SPMS patients. Mo‐MDSCs within SPMS exhibited decreased mRNA expression of interleukin‐10 and heme oxygenase 1 compared to RRMS and HC. Analysis of T‐cell regulatory function of Mo‐MDSCs demonstrated T‐cell suppressive capacity in RRMS and HCs, while Mo‐MDSCs of SPMS promoted autologous T‐cell proliferation, which aligned with a differential cytokine profile compared to RRMS and HCs. This study is the first to show phenotypic and functional shifts of MDSCs between clinical stages of MS, suggesting a role for MDSCs as a therapeutic target to prevent MS disease progression.

Cookies & analyse de trafic

M NADIR KADRI

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (18) — classées par pathologie

Transversal7

Gériatrie6

Essai clinique1

Lupus1

Maladie de Horton1

Pharmacovigilance1

Qualité de vie / PROMs1

Vascularites1

Datasets & protocoles partagés

Partager cette fiche